Read More Pharma Industry News DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2… bySrinathSeptember 18, 2021
